

ASSESSMENT OF THE PERFORMANCE OF THE PILLCAM COLON CAPSULE IN CROHN'S DISEASE BEFORE AND AFTER TREATMENT WITH ANTI-TNF

No registrations found.

Ethical review	Positive opinion
Status	Recruiting
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON22197

Source

NTR

Brief title

Pillcam 2

Health condition

Crohn's disease, ziekte van Crohn

Sponsors and support

Primary sponsor: Academic Medical Center, Amsterdam

Source(s) of monetary or material Support: Given Imaging, Israel.

Intervention

Outcome measures

Primary outcome

Sensitivity of PCCE2 to detect mucosal changes after treatment with the anti-TNF agents

(Infliximab or Adalimumab).

Secondary outcome

Determine inter-observer variability by serial readings of Pillcam recordings (one local reading and one central reading)

Correlations will be analyzed of PCCE 2 findings and serum CRP and fecal calprotectin levels.

Study description

Background summary

The goals of treatment in Crohn's disease have evolved in recent years from symptom control to healing of mucosal lesions, usually visualized by endoscopy. Potent therapeutic agents, such as anti-TNF agents, have made restoration of mucosal integrity attainable in a significant proportion of patients. Moreover, anti-TNF therapy was shown to be more effective in patients that had visible ulcers on endoscopy than in patients without such lesions. This means that clinicians are recommended to check for the presence of ulcers before they embark on biological therapy. Finally, endoscopic evaluation of treatment effects in Crohn's disease has entered routine practice. However, endoscopic procedures are time consuming, invasive and unpleasant for the patient. Surrogate markers for the severity of inflammation such as faecal calprotectin are under investigation. Magnetic resonance enterography was shown to nicely parallel with the severity of inflammation seen at endoscopy, but also this diagnostic tool is expensive and time consuming.

The development of a simple alternative to optical colonoscopy to assess mucosal inflammation in patients with Crohn's disease would therefore be of extreme importance. A reliable Pillcam examination is high on the priority list of potential options.

Recently, a multicenter study was performed that assessed safety and feasibility of PCCE-2 in evaluating the severity of mucosal inflammation in patients with ileocolonic Crohn's disease (1). Substantial agreement was found between PCCE-2 and conventional colonoscopy for the assessment of mucosal disease activity. Moreover, PCCE-2 was better tolerated than colonoscopy in these patients.

20 pts with active ileocolonic Crohn's disease undergoing capsule endoscopy using the second generation Pillcam capsule (PCCE 2) instead of a colonoscopy before and 8-12 weeks after treatment initiation with Infliximab or Adalimumab

Study objective

The goals of treatment in Crohn's disease have evolved in recent years from symptom control to healing of mucosal lesions, usually visualized by endoscopy. Potent therapeutic agents, such as anti-TNF agents, have made restoration of mucosal integrity attainable in a significant proportion of patients. Moreover, anti-TNF therapy was shown to be more effective in patients that had visible ulcers on endoscopy than in patients without such lesions. This means that clinicians are recommended to check for the presence of ulcers before they

embark on biological therapy. Finally, endoscopic evaluation of treatment effects in Crohn's disease has entered routine practice.

However, endoscopic procedures are time consuming, invasive and unpleasant for the patient. Surrogate markers for the severity of inflammation such as faecal calprotectin are under investigation. Magnetic resonance enterography was shown to nicely parallel with the severity of inflammation seen at endoscopy, but also this diagnostic tool is expensive and time consuming.

The development of a simple alternative to optical colonoscopy to assess mucosal inflammation in patients with Crohn's disease would therefore be of extreme importance. A reliable Pillcam examination is high on the priority list of potential options.

Recently, a multicenter study was performed that assessed safety and feasibility of PCCE-2 in evaluating the severity of mucosal inflammation in patients with ileocolonic Crohn's disease (1). Substantial agreement was found between PCCE-2 and conventional colonoscopy for the assessment of mucosal disease activity. Moreover, PCCE-2 was better tolerated than colonoscopy in these patients.

Study design

Before and 8-12 weeks after the start of treatment with anti-TNF agents

Intervention

20 patients with symptoms of active (ileo)colonic Crohn's disease and biochemical evidence of active inflammation (reflected by elevated faecal calprotectin (> 250 ug/g) and/or increased CRP serum levels (i.e. > 5 mg/l)) that need an endoscopic evaluation before starting anti-TNF treatment (Infliximab or Adalimumab) will be invited to take part in this study. Patients will undergo capsule endoscopy using PCCE 2 instead of colonoscopy before starting anti-TNF. After 8-12 weeks of treatment the PCCE-2 procedure will be repeated.

Contacts

Public

Academic Medical Center
Department of Gastroenterology and Hepatology
Meibergdreef 9
M. Löwenberg
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5667621

Scientific

Academic Medical Center

Department of Gastroenterology and Hepatology

Meibergdreef 9
M. Löwenberg
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5667621

Eligibility criteria

Inclusion criteria

Active ileocolonic Crohn's disease with CDAI > 150 points

- Elevated faecal calprotectin >250 ug/g and/or increased CRP levels (> 5 mg/l)
- Colon imaging clinically indicated in order to determine disease activity before embarking on anti-TNF treatment
- Prior documentation of colonic involvement by Crohn's disease in at least two colonic segments and documentation of colonic ulcers
- Ability to give informed consent and willing to undergo 2 Pillcam examination within 4 months

Exclusion criteria

- Any contraindication for colon capsule examination including swallowing disorders, severe congestive heart failure, renal insufficiency, or co-morbidities contraindicating these procedures.
- More than 1 bowel resection for CD
- Previous subtotal or total colectomy
- Active (draining) fistulas
- Proximal small bowel disease
- Known small bowel strictures

- High suspicion of small bowel strictures or colonic strictures.
In case of low suspicion of small bowel strictures patients have to undergo a test with the Agile patency capsule approximately 1 week prior to participation in the current study
- Short bowel or all stoma
- Need for MRI before capsule excretion
- Pacemaker or ICD
- Current pregnancy
- Current participation in an experimental clinical study
- Age younger than 18 years

Study design

Design

Study type:	Interventional
Intervention model:	Other
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	16-06-2016
Enrollment:	20
Type:	Anticipated

Ethics review

Positive opinion	
Date:	13-10-2016

Application type:

First submission

Study registrations

Followed up by the following (possibly more current) registration

ID: 50462

Bron: ToetsingOnline

Titel:

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL5585
NTR-old	NTR6177
CCMO	NL55599.018.16
OMON	NL-OMON50462

Study results